Clinical Studies With Cloxacillin

Publisher Website
Google Scholar
Abstract
A new semisynthetic penicillinase-resistant penicillin, cloxacillin, was used in treatment of 100 hospitalized patients with severe infections. Twenty-three of 25 patients with staphylococcal infections, 30 of 37 with pneumococcal infections, all 13 patients with streptococcal infection, and 17 of 25 with infection due to a variety of organisms responded favorably. At the present time, the drug is available only in oral-dosage form, limiting its use in severely ill patients. A toxic effect on the gastrointestinal tract was not observed; rashes developed in two patients. Serious superinfections occurred in at least three patients with pneumococcal pneumonia. Cloxacillin compares favorably with other semisynthetic penicillinaseresistant penicillins now available in the oral-dosage form.

This publication has 1 reference indexed in Scilit: